{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 376109547
| IUPAC_name = (2''E'')-''N''-methyl-''N''-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine
| image = Naftifine.svg
<!--Clinical data-->
| tradename = Exoderil
| Drugs.com = {{drugs.com|monograph|naftifine-hydrochloride}}
| MedlinePlus = a688020
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 65472-88-0
| ATC_prefix = D01
| ATC_suffix = AE22
| PubChem = 47641
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00735
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 66071
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 4FB1TON47A
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 626
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7451
<!--Chemical data-->
| C=21 | H=21 | N=1
| molecular_weight = 287.398 g/mol
}}
'''Naftifine''' (brand name Exoderil) is an allylamine [[antifungal drug]] for the topical treatment of [[tinea pedis]], [[tinea cruris]], and [[tinea corporis]] (fungal infections).

Naftifine has triple action: antifungal, antibacterial and anti-inflammatory. Its precise mechanism of action is unknown, but may involve selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme.<ref name="Robertson">Robertson Dirk B, Maibach Howard I, "Chapter 61. Dermatologic Pharmacology" (Chapter). Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor: Basic & Clinical Pharmacology, 11e: http://www.accesspharmacy.com/content.aspx?aID=4517257.</ref><ref name="Micromedex">Micromedex DRUGDEX Drug Point: Naftifine Hydrochloride. Accessed at [http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/7ED8A6/DUPLICATIONSHIELDSYNC/89971B/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/390170/ContentSetId/100/SearchTerm/naftifine/SearchOption/BeginWith#secN10184 www.thomsonhc.com/../BeginWith#secN10184], February 18, 2010.</ref> The half-life is approximately 2â€“3 days.<ref name="Micromedex"/> The metabolites are excreted in the urine and feces.<ref>AccessPharmacy: Drug Monographs: Naftifine. Accessed at http://www.accesspharmacy.com/drugContentPopup.aspx?mid=6620&section=10, February 18, 2010.</ref>

==References==
<references/>

{{Antifungals}}

[[Category:Antifungals for dermatologic use]]
[[Category:Naphthalenes]]
[[Category:Alkene derivatives]]

{{dermatologic-drug-stub}}